▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #567 by analyst upside · 2026-09-27
CUE
Cue Biopharma, Inc.
Healthcare · Market Cap $228M · P/E 0x
ANALYST PRICE TARGET
+180.2%
implied upside to consensus target
Current Price $31.41
Consensus Target $88.0
Bull Target $115.0
Bear Target $66.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
3
Hold
0
Sell
0
52-Week Low $4.98
52-Week High $45.5
YTD Return +210.7%
FUNDAMENTALS
Market Cap $228M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-29.46
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $38M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.98
52-Week High $45.5
Current Price $31.41
Bear Target $66.0
Bull Target $115.0
● Now $31.41 ● Target $88.0
TRADING DATA
Avg Volume 260K
YTD Return +210.7%
Analyst Count 3
Consensus Buy
Upside to Target +180.2%
Last Updated 2026-09-27

ANALYST SUMMARY

Cue Biopharma, Inc. (CUE) is currently trading at $31.41 with a Wall Street consensus price target of $88.0, implying potential upside of 180.2% over the next 12 months. 3 analysts currently cover CUE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $115.0, while the most cautious has a target of $66.0.

CUE operates in the Healthcare sector with a market capitalisation of $228M. The stock is up 210.7% year-to-date and is currently trading near the upper end of its 52-week range of $4.98 – $45.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AGEN +208.4%
Agenus Inc.
$386M · P/E 2.8x · Buy
CGEN +93.3%
Compugen Ltd.
$225M · P/E 6.3x · Buy
SABS +253.7%
SAB Biotherapeutics, Inc.
$299M · P/E 13.7x · Buy
WW +97.4%
WW International, Inc.
$144M · P/E 1.6x · Hold
XFOR +285.4%
X4 Pharmaceuticals, Inc.
$298M · P/E 2.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CUE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B. Riley Securities ● Initiated
Buy 2026-09-18 17% win rate (6 calls)
LUCID CAPITAL MARKETS ● Initiated
Buy 2025-08-25 40% win rate (5 calls)
Citizens Capital Markets reit
Market Outperform → Market Outperform 2025-04-02 Building track record
Stifel - Reiterated
Buy → Buy 2024-08-20 Building track record
JMP Securities - Reiterated
Market Outperform → Market Outperform 2024-07-26 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2024-07-26 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →